AstraZeneca COVID Vaccine 79% Effective In U.S. Phase III Trial
March 22, 2021 at 11:54 AM EDT
The AstraZeneca U.S. Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization.